Here, a systematic bioinformatics analysis combined with experiments can validate SLC25A32 as an innovative pan-cancer prognostic and immune-related biomarker and reveal its targetable mechanism of action in breast cancer. This evidence concerns the gene SLC25A32 and breast cancer.